Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient
- 12 February 2021
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (2) , 433-435
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Epstein–Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approachPathology, 2020
- Successful treatment of systemic EBV positive T-cell lymphoma of childhood using the SMILE regimenPediatric Hematology and Oncology, 2018
- Epstein-Barr Virus–Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO ClassificationJournal of Pathology and Translational Medicine, 2017
- Mature T‐ and NK‐cell non‐Hodgkin lymphoma in children and young adolescentsBritish Journal of Haematology, 2016
- Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal typeMedical Oncology, 2013
- Phase I study of dexamethasone, methotrexate, ifosfamide, l ‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemiaCancer Science, 2008
- First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphomaLeukemia & Lymphoma, 2006
- In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma‐derived cell line, NK‐YS, by etoposide and cyclosporine ABritish Journal of Haematology, 2001